Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study

Loras, Carme; Saro, Cristina; Gonzalez-Huix, Ferràn; Mínguez, Miguel; Merino, Olga; Gisbert, Javier P.; Barrio, Jesús; Bernal, Antonio; Gutiérrez, Ana; Piqueras, Marta; Calvet, Xavier; Andreu, Montserrat; Abad, Agueda; Ginard, Daniel; Bujanda, Luis; Panés, Julián; Torres, Miquel; Fernéndez-Bañares, Fernando; Viver, Josep M.; Esteve, Maria
January 2009
American Journal of Gastroenterology;Jan2009, Vol. 104 Issue 1, p57
Academic Journal
OBJECTIVES: Limited information suggests the existence of a high prevalence of hepatitis B (HBV) and C virus (HCV) infection in inflammatory bowel disease (IBD). This knowledge is relevant because the viruses may reactivate under immunosuppressive therapy. The objectives of this study are to assess the prevalence of HBV and HCV infection in IBD, in a nationwide study, and to evaluate associated risk factors. METHODS: This cross-sectional multicenter study included 2,076 IBD patients, consecutively recruited in 17 Spanish hospitals. Factors related to IBD (severity, invasive procedures, etc.) and to infection (transfusions, drug abuse, etc.) were registered. Independent risk factors for viral infection were evaluated using logistic regression analysis. RESULTS: Present and/or past HBV and HCV infection was found in 9.7% of patients of both ulcerative colitis (UC) and Crohn's disease (CD) (UC: HBsAg 0.8%, anti-HBc 8%, anti-HCV 1.3% ; CD: HBsAg 0.6%, anti-HBc 7.1%, anti-HCV 2.3%). Effective vaccination (anti-HBs, without anti- HBc) was present in 12% of patients. In multivariate analysis, age (odds ratio (OR) 1.04; 95% confidence interval (CI) 1.02 - 1.06; P = 0.000), family history of hepatitis (OR 2.48; 95% CI 1.3 - 4.74; P = 0.006) and moderate-to-severe IBD disease (OR 2.5; 95% CI 1.02 - 6.15; P = 0.046) were significantly related to HBV, whereas transfusions (OR 2.66; 95% CI 1.2 - 5.87; P = 0.015) and antibiotic use (OR 2.66; 95% CI 1.1 - 6.3; P = 0.03) were significantly related to HCV. The significance for transfusions was lost if they were administered after 1991, when HCV markers became mandatory in blood banks. CONCLUSIONS: Prevalence of HBV and HCV infection in IBD is similar to that of the general population of reference and lower than that in previously published series. This fact, in addition to the lack of association with invasive procedures, suggests the existence of adequate preventive measures in centers attending to these patients. The low percentage of effective vaccination makes it mandatory to intensify B virus vaccination in IBD.


Related Articles

  • Clostridium difficile and Inflammatory Bowel Disease (IBD). Deresinski, Stan // Clinical Infectious Diseases;9/1/2009, Vol. 49 Issue 5, piii 

    The article presents the analysis of the author on the study conducted regarding an assessment for the relations of Clostridium (C) difficile and inflammatory bowel disease (IBD). The researchers have determined the association of C. difficile in patients with IBD as the rate of carriage...

  • Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. Kverka, Miloslav; Rossmann, Pavel; Tlaskalova-Hogenova, Helena; Klimesova, Klara; Jharap, Bindia; de Boer, Nanne K.; Vos, Rene M.; van Bodegraven, Adriaan A.; Lukas, Milan; Mulder, Chris J. // BMC Gastroenterology;2011, Vol. 11 Issue 1, p47 

    Background: Oral thiopurines are effective and widely used in treatment of inflammatory bowel disease (IBD) in humans, although their use is limited due the development of adverse events. Here, we examine the efficacy and toxicity of oral treatment with 6-tioguanine (6-TG) and azathioprine (AZA)...

  • Patients with Inflammatory Bowel Disease Have a Lower Response Rate to HBV Vaccination Compared to Controls. Altunöz, Mustafa; Şenateş, Ebubekir; Yeşil, Atakan; Çalhan, Turan; Övünç, Ayşe // Digestive Diseases & Sciences;Apr2012, Vol. 57 Issue 4, p1039 

    Background: Hepatitis B (HBV) is a vaccine-preventable infection that may cause severe infections, particularly in patients who are being treated with immunosuppressive therapy [(i.e., inflammatory bowel disease (IBD)]. Limited data are available about IBD patients' response rate to HBV vaccine....

  • Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Beaugerie, Laurent; Gerbes, Alexander L. // Gut;Oct2010, Vol. 59 Issue 10, p1310 

    The article discusses research about the effectiveness of immunosuppressive treatment of liver dysfunction with inflammatory bowel disease. Topics mentioned include the possible side effects of immunosuppressive drugs, complexity of reactivation of hepatitis B and C under immunosuppressive...

  • Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Loras, C.; Gisbert, J. P.; Mínguez, M.; Merino, O.; Bujanda, L.; Saro, C.; Domenech, E.; Barrio, J.; Andreu, M.; Ordás, I.; Vida, L.; Bastida, G.; González-Huix, F.; Piqueras, M.; Ginard, D.; Calvet, X.; Gutiérrez, A.; Abad, A.; Torres, M.; Panés, J. // Gut;Oct2010, Vol. 59 Issue 10, p1340 

    Background There is no information about the frequency of liver dysfunction in patients with inflammatory bowel disease (IBD) treated with immunosuppressants and infected with hepatitis B (HBV) and/or C virus (HCV). Aim To assess the influence of immunosuppressants on the course of HBV and HCV...

  • Clinical epidemiology -- how important now? Binder, V // Gut;May2005, Vol. 54 Issue 5, p574 

    The article focuses on the putative risk of haematopoietic cancer in relation to modern strong immunosuppressive treatment in inflammatory bowel disease. The natural history of a chronic disease should ideally be the background for any therapeutic trial. Modern information technology has...

  • Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Sokol, H.; Beaugerie, L. // Gut;Oct2009, Vol. 58 Issue 10, p1427 

    The risk of lymphoproliferative disorders (LDs) has become a major concern for clinicians managing patients with inflammatory bowel disease (IBD). Yet it is difficult to distinguish the possible responsibility of immunosuppressive therapy from the background risk due to the inflammatory disorder...

  • The Mushroom Agaricus blazei Murill Extract Normalizes Liver Function in Patients with Chronic Hepatitis B. Chung-Hua Hsu; Kung-Chang Hwang; Yi-Hsiung Chiang; Pesus Chou // Journal of Alternative & Complementary Medicine;Apr2008, Vol. 14 Issue 3, p299 

    Background: Hepatitis B is a global health problem. Use of complementary and alternative medicine has been popular among patients with hepatitis B. This 1-year open-label pilot study aims to observe whether Agaricus blazei Murill extract improves liver function in patients with hepatitis B....

  • Mercaptopurine.  // Reactions Weekly;1/30/2016, Vol. 1586 Issue 1, p196 

    An abstract of the article "A novel presentation of 6-mercaptopurine toxicity in a patient with IBD" by Z.C. Junga and others is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics